Melanocyte protein PMEL · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Melanocyte protein PMEL shows approved-linked disease relevance led by melanoma. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P40967. Start with melanoma, then reuse UniProt P40967 as the stable protein anchor across project notes and exports.
Start with melanoma, then reuse UniProt P40967 as the stable protein anchor across project notes and exports.
Melanocyte protein PMEL shows approved-linked disease relevance led by melanoma. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with melanoma because it currently carries approved-linked support. Linked drugs include TEBENTAFUSP. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyMelanocyte protein PMEL
Review this target as Melanocyte protein PMEL, mapped to UniProt P40967. Sequence length is 661 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Melanocyte protein PMEL as ChEMBL target CHEMBL3712988, mapped to UniProt P40967. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Melanocyte protein PMEL is the right protein anchor across sources, using UniProt P40967 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why melanoma is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Melanocyte protein PMEL |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P40967 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Melanocyte protein PMEL |
| UniProt Accession | P40967 |
| Component Type | Protein |
| Sequence Length | 661 aa |
Melanocyte protein PMEL
Review this target as Melanocyte protein PMEL, mapped to UniProt P40967. Sequence length is 661 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Melanocyte protein PMEL shows approved-linked disease relevance led by melanoma. 3 more disease programs remain visible in the same review block.
Start review with melanoma because it currently carries approved-linked support. Linked drugs include TEBENTAFUSP. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.